Why clinical trial data and post-market experience may differ
The Caya® diaphragm has been available internationally in 30 countries since 2013 and is used worldwide.
Experience gained from post-market use (‘post-market surveillance’) can provide additional insights into everyday use. However, such data cannot be directly compared with clinical trials.
The reason:
In clinical trials, pregnancies are actively and systematically recorded according to fixed criteria. Post-market feedback, on the other hand, is usually based on voluntary reports and does not fully capture all uses or pregnancies.
Post-market data can therefore provide supplementary safety information, but cannot replace controlled clinical efficacy trials. The data collected since the product’s launch is significantly more extensive and provides stronger evidence than the clinical trials. As the manufacturer, we have received reports of only 38 unintended pregnancies in the 13 years since over 500,000 Caya diaphragms were placed on the market. Statistically speaking, this figure should be higher. Furthermore, reports of side effects from users are recorded and evaluated. Since its market launch 13 years ago, no new or previously unknown side effects have been recorded. The Caya diaphragm therefore has an established safety profile and many years of post-market experience.
________________________________________________________________________________________________________